Our global life sciences company brings diagnostic testing & drug development together.

Labcorp is Advancing Testing for Alzheimer’s Disease (AD) Through Biogen's Amyloid βeta Confirmed™ Program

Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a CSF patient sample and computes the ratio of those proteins, providing an indication of AD pathology:

  • Through the Amyloid Beta ConfirmedTM program, sponsored by Biogen*, Labcorp is providing beta-amyloid 42/40 ratio testing at no cost† to patients. To learn more about the program, visit:
  • The test is intended for patients being evaluated for mild cognitive impairment (MCI) or mild dementia clinical stages of Alzheimer's disease.
  • The test measures the amount of  beta-amyloid 42 and 40 proteins in the CSF and computes the ratio.
  • Ratios <0.058 indicate a higher likelihood of a patient having a clinical diagnosis of AD.

Test Information

Test Name Beta Amyloid 42/40 Ratio, CSF
Test Number 505505
Volume (min-max) 5mL – 8mL
Collection tube Sarstedt® 62.610.018 10mL tube only
Centrifugation No
Refrigeration Required; refrigerate immediately after collection

Not a Labcorp Client?

Click here to provide us your information and a sales rep will be in touch shortly.

This assay is currently not available in New York state.


  1. Palmqvist S, Zetterberg H, Mattsson N, “Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.” Neurology. 2015; 85:1–10.
  2. Hansson O, Seibyl J, Stomrud E, “CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.” Alzheimer’s & Dementia. 2018; 14(11): P1470-1481.
  3. Lewczuk P, Matzen A, Blennow K, “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease.” J Alzheimers Dis. 2017; 55(2): P813–822.
  4. Baldeiras I, Santana I, Leitão MJ, “Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer’s disease dementia in mild cognitive impairment.” Alzheimer's Research & Therapy. 2018; 10, 33.